Multiple MyelomaAmyloidosisCryoglobulinemiaCastleman's DiseaseLight Chain Deposition DiseaseHeavy Chain Deposition DiseasePolyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin ChangesSmoldering Multiple MyelomaPlasma Cell LeukemiaMonoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Renal Significance (MGRS)Monoclonal Gammopathy of Neurological Significance (MGNS)
Investigational drug(s) / intervention(s)
No intervention
No intervention: No intervention
Study summary
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
1. Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)
2. Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).
3. Patients are included into this cohort after signing the ICFs.
Exclusion Criteria:
Significant comorbidity may be life-threatening.
Primary outcome measure(s)
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH — 10 years To measure the treatment response in the cohort study of PCDs in PKUFH.The treatment response is done according to the criteria of the International Myeloma Working Group (IWMG) of 2016.
Trial sites (1)
Facility
City
Region
Status
Peking University First Hospital
Beijing
China
Recruiting
More Peking University First Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.